Minocycline Accelerates Intracerebral Hemorrhage Absorption

• Status: Not yet recruiting
• Trial end date: 2024-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Minocycline has been found to reduce cerebral edema secondary to cerebral hemorrhage, promote hematoma absorption, and shorten hematoma absorption time; clinical studies have been conducted to confirm the safety in the treatment, but no significant hematoma absorption effect was seen with short duration of drug use. Therefore, the investigators propose to conduct a multicenter randomized controlled clinical trial to determine its accelerating effect on hematoma absorption.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
• Collaborators: The Fourth Affiliated Hospital of Zhejiang University School of Medicine; The Second Affiliated Hospital of Jiaxing University
• Treatments: Minocycline

Criteria

Inclusion Criteria:

• 18-80 years old

• Spontaneous intracerebral hemorrhage by CT scan

• Intracerebral hematoma volume is less than 16ml

• No surgical treatment of hematoma evacuation

Exclusion Criteria:

• Allergies to tetracycline antibiotics

• Pregnancy or suspected pregnancy (pregnancy test will be done on women with fertility potential)

• Hepatic and/or renal insufficiency

• Glasgow Coma Scale of 5 or less

• Secondary cerebral hemorrhage caused by trauma, arteriovenous malformation, aneurysm, tumor or other reasons

• Thrombocytopenia (platelet count<75000/mm3) or coagulation dysfunction (INR>1.4)

• Incapable to take care of themselves in past life (score of Rankin scale before stroke>2)

• Signed DNR (Do Not Resuscitate)